Nkarta Reports Third Quarter 2022 Financial Results and Corporate Highlights
09 nov. 2022 16h02 HE
|
Nkarta, Inc.
NKX101 and NKX019 allogeneic cell therapy programs continue to advance following initial clinical data reported in April 2022NKX019 Phase 1 clinical trial recently opened dose expansion cohortsNKX019...
Nkarta Presents Data Supporting Engineered NK Cell Based Combination Therapies and Next Generation Commercial-Scale Manufacturing Platform at SITC 37th Annual Meeting
07 nov. 2022 08h52 HE
|
Nkarta, Inc.
Improved Anti-Tumor Activity Demonstrated by the Combination of NKX019 and a CD20-directed Monoclonal Antibody in Preclinical Models Pulsed Stimulation of NK Cells Derived from Peripheral Blood of...
Nkarta to Participate at Upcoming Investor Conferences
02 nov. 2022 08h02 HE
|
Nkarta, Inc.
SOUTH SAN FRANCISCO, Calif., Nov. 02, 2022 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat cancer,...
Nkarta Reports Second Quarter 2022 Financial Results and Corporate Highlights
11 août 2022 16h02 HE
|
Nkarta, Inc.
Positive preliminary data from NKX101 Phase 1 study in patients with relapsed / refractory AML and NKX019 Phase 1 study in patients with relapsed / refractory NHL validate the company’s platform for...
Nkarta Announces Key Senior Leadership Team Appointments
25 juil. 2022 16h31 HE
|
Nkarta, Inc.
Ralph Brandenberger, PhD, promoted to Chief Technical OfficerYvonne Li, MBA, promoted to Chief Administrative OfficerEvolution of Nkarta leadership team to support rapid development of allogeneic,...
Nkarta to Participate at Upcoming Investor Conference
31 mai 2022 07h02 HE
|
Nkarta, Inc.
SOUTH SAN FRANCISCO, Calif., May 31, 2022 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat cancer, today...
Nkarta Appoints David R. Shook, MD, as Vice President, Clinical Development
16 mai 2022 16h02 HE
|
Nkarta, Inc.
SOUTH SAN FRANCISCO, Calif., May 16, 2022 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies to...
Nkarta Reports First Quarter 2022 Financial Results and Corporate Highlights
12 mai 2022 16h02 HE
|
Nkarta, Inc.
Positive preliminary data reported from NKX101 Phase 1 study in patients with relapsed / refractory AML; 3 of 5 patients treated with a 3-dose regimen of 1B or 1.5B CAR NK cells per dose achieved...
Nkarta Announces Closing of Upsized Public Offering of Common Stock and Underwriters’ Full Exercise of Option to Purchase Additional Shares
28 avr. 2022 16h01 HE
|
Nkarta, Inc.
SOUTH SAN FRANCISCO, Calif., April 28, 2022 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer cell therapies to treat cancer, today...
Nkarta Announces Pricing of Upsized Public Offering of Common Stock
25 avr. 2022 23h19 HE
|
Nkarta, Inc.
SOUTH SAN FRANCISCO, Calif., April 25, 2022 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer cell therapies to treat cancer, today...